Hebei Senlangbio Biotechnology Overview

  • Year Founded
  • 2016

Year Founded

  • Status
  • Private

  • Employees
  • 160

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $30.2M

  • Investors
  • 1

Hebei Senlangbio Biotechnology General Information

Description

Developer of immunotherapy antibody drugs designed to treat malignant tumors. The company's drugs are based on CAR-T/TCR-T, universal CAR-GDT, and CAR-HSPC-NK technology that helps to evaluate the efficacy and safety of chimeric antigen receptor T cell immunotherapy (CAR-T) in the treatment of hematopoietic and lymphoid malignancies, enabling patients with relapsed or refractory blood for immune cell therapy including ALL and B-cell Lymphoma.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Room 512 and 513, Building 1, 136 Yellow River Avenue
  • High-Tech Development Zone
  • Shijiazhuang, Hebei 050035
  • China
+86 0311
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • Room 512 and 513, Building 1, 136 Yellow River Avenue
  • High-Tech Development Zone
  • Shijiazhuang, Hebei 050035
  • China
+86 0311

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Hebei Senlangbio Biotechnology Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 18-May-2022 $30.2M Completed Generating Revenue
1. Merger/Acquisition 14-Jun-2021 Completed Generating Revenue
To view Hebei Senlangbio Biotechnology’s complete valuation and funding history, request access »

Hebei Senlangbio Biotechnology Patents

Hebei Senlangbio Biotechnology Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025190367-A1 Anti-cldn18.2 nanobody, chimeric antigen receptor, and uses thereof Pending 13-Mar-2024
EP-4591877-A1 Novel marrow-infiltrating lymphocytes population comprising chimeric antigen receptor specific for bcma and producing method for the same Pending 24-Jan-2024
WO-2025159236-A1 Novel population of marrow-infiltrating lymphocytes comprising bcma-specific chimeric antigen receptor and method for preparing same Pending 24-Jan-2024
AU-2023418711-A1 Nanobody targeting bcma, chimeric antigen receptor and use thereof Pending 26-Dec-2022
EP-4644418-A1 Nanobody targeting bcma, chimeric antigen receptor and use thereof Pending 26-Dec-2022 C07K16/2878
To view Hebei Senlangbio Biotechnology’s complete patent history, request access »

Hebei Senlangbio Biotechnology Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Hebei Senlangbio Biotechnology Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds
Qianhai FoF Fund of Funds Minority
To view Hebei Senlangbio Biotechnology’s complete investors history, request access »

Hebei Senlangbio Biotechnology FAQs

  • When was Hebei Senlangbio Biotechnology founded?

    Hebei Senlangbio Biotechnology was founded in 2016.

  • Where is Hebei Senlangbio Biotechnology headquartered?

    Hebei Senlangbio Biotechnology is headquartered in Shijiazhuang, China.

  • What is the size of Hebei Senlangbio Biotechnology?

    Hebei Senlangbio Biotechnology has 160 total employees.

  • What industry is Hebei Senlangbio Biotechnology in?

    Hebei Senlangbio Biotechnology’s primary industry is Drug Discovery.

  • Is Hebei Senlangbio Biotechnology a private or public company?

    Hebei Senlangbio Biotechnology is a Private company.

  • What is the current valuation of Hebei Senlangbio Biotechnology?

    The current valuation of Hebei Senlangbio Biotechnology is .

  • What is Hebei Senlangbio Biotechnology’s current revenue?

    The current revenue for Hebei Senlangbio Biotechnology is .

  • How much funding has Hebei Senlangbio Biotechnology raised over time?

    Hebei Senlangbio Biotechnology has raised $30.2M.

  • Who are Hebei Senlangbio Biotechnology’s investors?

    Qianhai FoF has invested in Hebei Senlangbio Biotechnology.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process